Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis

Background: The synergistic effects of antiangiogenic inhibitor bevacizumab and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) therapy were encouraging in patients with EGFR-mutant advanced NSCLC, though some controversy remains. The specific subgroup of patients who might be...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Haosheng Zheng, Xianyu Qin, Yuzhen Zheng, Xingping Yang, Jian Tan, Weijie Cai, Shiyun He, Hongying Liao
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2024-01-01
Edice:	Frontiers in Pharmacology
Témata:	EGFR NSCLC bevacizumab EGFR-TKI combination therapy
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1238579/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!